Search

Efalizumab

Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.

Idraparinux

As a result, Sanofi stopped the development of the drug. … Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.

ISIS 325568

ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR).

Onercept

SPP 301

SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.

Lysozyme

Faropenem medoxomil

Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc. … Faropenem medoxomil is an ester prodrug derivative of the beta-lactam antibiotic [faropenem].

CYT007-TNFQb

CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.

ADX-10061

ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

Bergapten

Bergapten is under investigation in clinical trial NCT00533195 (Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis).